Applications of Isotopes in Medicine and Life Sciences - Current and Future Trends
Held: September 28, 2022
During the last decades, the ecosystem of isotopes and their applications has been rapidly evolving. As noted in the first 11ICI webinar, the trend is to enhance the potential of precise medicine, develop new therapeutic agents and targeted therapies.
This webinar brings together specialists from the leading nuclear medicine organizations, industry, and academia for an open discussion regarding the current and future trends on applications of isotopes in medicine and the life sciences.
Watch the Recording:
Welcome Remarks
Jong Kyung Kim
President World Council on Isotopes
Moderator
Alan Packard
Associate Professor of Radiology
Harvard School of Medicine
Jong Kyung Kim is a professor emeritus in the department of Nuclear Engineering at Hanyang University in Korea.
He had a particular responsibility for the preparation of the national promotion plan for the utilization of radiation and radioisotopes in Korea (2001-2007).He was a commissioner of the Korea Atomic Energy Commission (2010-2013). He was president of Korean Nuclear Society (KNS/ 2013-2014).
He was a member of the Standing Advisory Group on Nuclear Energy (SAGNE/ 2014-2017) of the IAEA. He was the past president of Korea Atomic Energy Research Institute (KAERI/ 2014-2017). He is an executive council (EC) member (2008-2021) and vice-president for congress affairs (2016-2021) of the International Radiation Protection Association (IRPA). He is currently serving as president of the 15th International Congress of IRPA, IRPA 15. He served on the International Monitoring and Steering Committee (IMSC) for 6ICI and the Executive Committee (EC) for 7ICI-10ICI. He is the president of WCI (2020.2-2022.6).
He has a bachelor’s degree from SUNY at Buffalo in nuclear engineering and a master’s degree and Ph.D. (1986) in the same discipline from the University of Michigan in USA.
Alan Packard, PhD, is associate professor of radiology at Harvard Medical School, and director of radiopharmaceutical research and a senior research associate in nuclear medicine at Boston Children's Hospital.
His laboratory at Boston Children’s Hospital is engaged in the development of radiolabeled proteins for multiple applications, including cancer imaging and therapy, and the development of 18F-labeled small molecules for myocardial perfusion imaging. The focus of the cancer program is on developing copper-64- and zirconium-89-labeled antibodies that can be used to noninvasively evaluate disease status, as well as on developing antibodies labeled with therapeutic radionuclides such as lutetium-177 and copper-67 that can be used to treat cancer.
Dr. Packard has authored more than 80 peer-reviewed articles and book chapters on topics ranging from radionuclide generators to pediatric nuclear medicine and new synthetic methods for labeling small molecules with 18F. He is a regular lecturer and invited speaker at conferences across the United States and around the world. Dr. Packard has a bachelor’s degree in chemistry from the University of New Hampshire, earned his PhD in inorganic chemistry at Colorado State University, and did his postdoctoral research in technetium chemistry at the University of Cincinnati.
Industry Experts
Keon W. Kang
Dr. Keon W. Kang, a nuclear medicine physician, is a professor of the Department of Nuclear Medicine, Seoul National University Hospital and Vice Director of Bio-MAX Institute, Seoul National University.
He received an M.D. degree from Seoul National University College of Medicine (1991). He received Ph.D. in Medical Science at Seoul National University College of Medicine (2001). He has worked as Chief, Department of Nuclear Medicine, National Cancer Center, Korea (2000-2007). He studied in vivo molecular imaging at Prof. Sam Gambhir’s lab as a visiting scientist at Stanford (2003-2004). His research areas are in vivo molecular imaging of cancer using PET & nanoparticles and radionuclide theranostics.
Clemens Decristoforo
Prof. Clemens Decristoforo is Radiopharmacist at the Department of Nuclear Medicine of the Medical University Innsbruck, Austria.
He studied Pharmacy and did his PhD in 1997 at the Leopold Franzens University. Innsbruck. In 1997-1998 he was a Post-Doc Marie Curie Research Fellow at the Nuclear Medicine Research Lab at St.Bartholomews Hosp., London and 2009-2010 he worked as radiopharmaceutical Scientist at the International Atomic Energy Agency in Vienna. In 2014 he was awarded honorary Professorship of the Medical University Innsbruck. He chaired for many years the Radiopharmacy Committee of the European Association of Nuclear Medicine, is member of Expert Group 14 of the European Pharmacopeia (EDQM, Strasbourg) and active in regulatory aspects of radiopharmaceuticals.
He is member of several editorial boards of journals in the field of radiopharmaceuticals, is teaching regularly for master students in Pharmacy and Molecular Medicine and supervises several PhD and Master students, current coordination the IGDT PhD programme of the Innsbruck PhD School for Biomedical Sciences. His research interests are focussed on radiometals and peptides for molecular imaging and therapy, in this field he has published more than 150 scientific papers.
Cathy S. Cutler
Cathy S. Cutler, Ph.D. is Director of the Medical Isotope Research Production and Development group (MIRP) at Brookhaven National
Laboratory.
Dr. Cutler earned the Bachelor of Sciences in Biochemistry in 1988 and a Doctorate in Inorganic Chemistry in 1993 from the University of Cincinnati. Dr. Cutler then joined the Radiation Sciences group at
Washington University School of Medicine and developed and characterized a Ga‐68 brain agent that crosses the intact blood brain barrier; designed studies to determine how in vivo metabolism affects compounds distribution, clearance and target selectivity; and collaborated to radiolabel and evaluate peptides containing unique amino acids with modified side chains to bind metals such as technetium, rhenium and rhodium. It was this collaboration that drew Dr. Cutler to the University of Missouri Research Reactor Centers Radiopharmaceuticals Group in 1998, where she worked until June 2015. Additionally, she directs the Target Processing Labs (TPL).
Dr. Cutler’s research focuses on developing production and separation methods for high specific activity radioisotopes, creating a suite of diagnostic and therapeutic agents tailored for individual needs, which has been funded by the DOE, NIH, NSF and public foundations.
She brings more than 20 years of experience in the development and evaluation of radiopharmaceuticals, utilizing bioinorganic and radioanalytical chemistry to develop and evaluate radiopharmaceuticals for both diagnosis and therapy.
Marian Meckel
Dr. Marian Meckel, Vice President Research and Development, ITM Isotopen Technologien Munchen
Dr. Meckel studied Biomedicine Chemistry and earned his Ph.D. in 2014 from the Institute from Nuclear Chemistry at the University of Mainz and the Max Planck Graduate Center.
Since 2015 he has been involved in radioisotope supply chain and Sales at ITM Isotope Technologies Munich SE. In 2018, Dr. Meckel joined ITM as Head of Production and more recently as Vice President Research and Development.
Dr. Meckel has conducted studies for the development of the ITM 68Ge/68Ga-Generator, scale-up processes for lanthanide separations as well as 68Ga-, 177Lu- and 225Ac-radiopharmaceuticals for clinical imaging and therapy. He has over 32 publications and patents.
CONFERENCE SECRETARIAT
c/o Venue West Conference Services
#449-1231 Pacific Boulevard
Vancouver, BC V6Z 0E2, Canada